With reports of bizarre sleep-walking side effects causing sales to plummet, Sanofi-Aventis, manufacturer of the sleep drug Ambien, has begun a new ad campaign. Analysts predict that a large-scale advertising war between Ambien and its competitors will soon follow.
Pfizer Inc., and their partner Neurocrine Sciences Inc., are planning to release a new pill, currently known as indiplon, that will compete with Ambien and Sepracor's Lunesta this summer. Ads are likely to flood the media.
Sleeping pill prescriptions increased 55 percent, to more than 45 million, over the course of four years. But publicity about negative side effects have caused Ambien sales to decline as much as 12 percent during March of this year.
Ambien, Lunesta, and indiplon are all in the same class of drugs, so they may all have similar side effects.
These warnings have been effective, as sales of sleep drugs have dropped all around. Now the manufacturers of Ambien and other worthless drugs are planning to flood the various media with ad campaigns similar to those shilling erectile dysfunction products that can make you go blind.
In fact, you won't be able to watch TV without seeing a commercial selling the highly questionable virtues of sleeping pills. However, you may not see much at all about Pfizer's new sleep aid indiplon this summer, because the multi-national drug corporation enacted a six-month delay on consumer ads last year.
That internal "ban" won't stop Pfizer detail persons from hounding your doctor about indiplon's virtues, however.
Stay tuned and aware of all the methods drugmakers use to sell their worthless products by reading my free newsletter. In the meantime, if you're having trouble sleeping, check out my extensive Guide to a Good Night's Sleep, which contains tips such as: